1700011M02Rik Activators
RAI1 Activators encompass a range of chemical compounds that indirectly stimulate the functional activity of RAI1 through various signaling cascades. Agents like Forskolin and Dibutyryl-cAMP exert their effects by increasing cAMP levels, thereby activating PKA, which is known to phosphorylate RAI1 and enhance its activity. Similarly, Rolipram, by inhibiting cAMP degradation, maintains elevated levels of PKA activity, facilitating the phosphorylation and subsequent activation of RAI1. Ionomycin and BAPTA-AM manipulate intracellular calcium levels, indirectly impacting calcium-dependent kinases such as CaMK, which may phosphorylate and activate RAI1. SKF-96365 and KN-93 also manipulate calcium signaling, with SKF-96365 inhibiting receptor-mediated calcium entry and KN-93 inhibiting CaMK; both of these actions can trigger compensatory mechanisms that could enhance RAI1 activity.
Further influencing the activity of RAI1 are compounds that modulate protein phosphorylation states, such as Okadaic acid, which inhibits the dephosphorylation of proteins, potentially leading to an enhanced phosphorylation state of RAI1. Chelerythrine, a PKC inhibitor, and PD-98059, a MEK inhibitor, shift signaling dynamics away from their respective pathways, which could result in the activation of alternative pathways that promote RAI1 activity. SB-202190, by inhibiting p38 MAPK, may also reroute signaling to pathways that lead to the activation of RAI1. Additionally, Anisomycin, by activating stress-activated protein kinaseslike JNK, may indirectly foster the phosphorylation of substrates that enhance RAI1's role. Collectively, these RAI1 Activators function through intricate biochemical pathways, leading to the modification of the phosphorylation landscape and calcium signaling, which are critical in supporting the heightened functional activity of RAI1 without directly affecting its expression levels or direct activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, enzymes that break down cAMP. By preventing cAMP degradation, IBMX can indirectly increase the activity of 1700011M02Rik by sustaining PKA activation and its downstream effects. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), which phosphorylates target proteins affecting various signaling pathways. PKC-mediated phosphorylation might enhance the activity of 1700011M02Rik by modulating proteins within its signaling network. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a kinase inhibitor with a broad range of targets. By inhibiting competitive kinase signaling, EGCG could enhance the signaling pathway specificity and activity of 1700011M02Rik. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, potentially activating calcium-dependent protein kinases which could phosphorylate and activate 1700011M02Rik or its associated proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which could augment 1700011M02Rik activity by reducing PI3K/AKT pathway activity, tipping the balance in favor of pathways in which 1700011M02Rik is involved. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate acts on its receptors to initiate signaling cascades, potentially enhancing the activity of 1700011M02Rik through sphingolipid signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 may upregulate alternative signaling routes, potentially increasing the functional activity of 1700011M02Rik. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187, a calcium ionophore, increases intracellular calcium, which can activate signaling pathways that may enhance the activity of 1700011M02Rik. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to increased cytoplasmic calcium levels, which may result in the activation of calcium-dependent pathways affecting 1700011M02Rik activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor that could, paradoxically, enhance 1700011M02Rik function by inhibiting kinases that negatively regulate pathways involving 1700011M02Rik. | ||||||